Elanco Mobilizes Full Product Portfolio to Combat New World Screwworm Outbreak in US
Summary
Elanco Animal Health is committing its full product portfolio to combat the New World Screwworm (NWS) outbreak, following the first confirmed case in U.S. livestock in Texas. The company is leveraging existing products, some with FDA Emergency Use Authorizations, to provide treatment and prevention options for livestock and pets. This proactive response positions Elanco as a critical solution provider against a significant new animal health threat, potentially boosting sales of its relevant products.
At the time of this announcement, ELAN was trading at $23.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.3B. The 52-week trading range was $13.14 to $27.72. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.